Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PRLX 93936 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2012 New trial record